Axsome Therapeutics, Inc. (AXSM)

Market Cap	7.77B
Revenue (ttm)	561.26M
Net Income (ttm)	-229.53M
Shares Out	50.41M
EPS (ttm)	-4.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	469,872
Open	155.36
Previous Close	154.70
Day's Range	152.41 - 158.56
52-Week Range	75.56 - 158.57
Beta	0.47
Analysts	Strong Buy
Price Target	176.00 (+14.15%)
Earnings Date	Nov 3, 2025

About AXSM

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 ago...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 19, 2015
• Employees: 683
• Stock Exchange: NASDAQ
• Ticker Symbol: AXSM
• Website: https://www.axsome.com

Financial Performance

In 2024, Axsome Therapeutics's revenue was $385.69 million, an increase of 42.53% compared to the previous year's $270.60 million. Losses were -$287.22 million, 20.1% more than in 2023.

Analyst Summary

According to 20 analysts, the average rating for AXSM stock is "Strong Buy." The 12-month stock price target is $176.0, which is an increase of 14.15% from the latest price.

Price Target

$176.0

(14.15% upside)

Analyst Consensus: Strong Buy